| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:JNJ-42253432
CAS:1428327-35-8
Purity:99.08% Package:1mg/RMB 1180;5mg/RMB 2930;10mg/RMB 4180
|
JNJ-42253432 manufacturers
- JNJ-42253432
-
- $118.00 / 1mg
-
2024-11-19
- CAS:1428327-35-8
- Min. Order:
- Purity: 99.08%
- Supply Ability: 10g
|
| | JNJ-42253432 Basic information |
| Product Name: | JNJ-42253432 | | Synonyms: | JNJ-42253432;JNJ42253432,JNJ 42253432;5-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-methyl-N-[[1-(4-phenyl-1-piperazinyl)cyclohexyl]methyl]-;JNJ-42253432, 10 mM in DMSO | | CAS: | 1428327-35-8 | | MF: | C28H38N4O | | MW: | 446.63 | | EINECS: | | | Product Categories: | | | Mol File: | 1428327-35-8.mol |  |
| | JNJ-42253432 Chemical Properties |
| Boiling point | 592.8±50.0 °C(Predicted) | | density | 1.130±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 16.14±0.20(Predicted) | | form | Solid | | color | White to off-white |
| | JNJ-42253432 Usage And Synthesis |
| Uses | JNJ-42253432 is a CNS-penetrant, high-affinity and orally active P2X7 antagonist, with pKi values of 9.1 and 7.9 for rat and human P2X7 channels, respectively[1]. | | Biological Activity | JNJ-42253432 is a CNS-penetrant, high-affinity and orally active P2X7 antagonist, with pKi values of 9.1 and 7.9 for rat and human P2X7 channels, respectively[1].
When dosed in rats, JNJ-42253432 occupied the brain P2X7 channel with an ED50 of 0.3 mg/kg, corresponding to a mean plasma concentration of 42 ng/ml. JNJ-42253432 also increased serotonin levels in the rat brain, which is due to antagonism of the serotonin transporter (SERT) resulting in an ED50 of 10 mg/kg for SERT occupancy[1]. | | in vivo | When dosed in rats, JNJ-42253432 occupied the brain P2X7 channel with an ED50 of 0.3 mg/kg, corresponding to a mean plasma concentration of 42 ng/ml. JNJ-42253432 also increased serotonin levels in the rat brain, which is due to antagonism of the serotonin transporter (SERT) resulting in an ED50 of 10 mg/kg for SERT occupancy[1]. | | References | [1]. Brian Lord, et al. Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. J Pharmacol Exp Ther. 2014 Dec;351(3):628-41. |
| | JNJ-42253432 Preparation Products And Raw materials |
|